Here below are the publications (8) participated by Davide Rossi along with Anastasios Stathis (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations).
Any wrong or incomplete data? Any missing, misplaced, unlicensed picture? Please report any abuse, inaccuracy or lack of information to info@ticinoscienza.ch

1) IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma
Haematologica, 22 febbraio 2024

2) PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine
bioRxiv, 16 novembre 2023

3) ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms
bioRxiv, 2 gennaio 2023

4) In vitro anti-lymphoma activity of the first-in-class pan-NOTCH transcription inhibitor CB-103
British Journal of Haematology, 9 dicembre 2022

5) SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
Blood Advances, 12 luglio 2022

6) Genetic and phenotypic attributes of splenic marginal zone lymphoma
Blood, 3 febbraio 2022

7) Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models
Haematologica, 1 novembre 2020

8) Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models.
American Society of Hematology, https://ashpublications.org/bloodadvances/article/4/5/819/452604/Copanlisib-synergizes-with-conventional-and
Davide Rossi
is currently collaborating with
Istituto Oncologico di Ricerca (IOR) (Rif. IOR)
Via Francesco Chiesa 5
6500 Bellinzona
Davide Rossi
on behalf of
Istituto Oncologico di Ricerca (IOR) USI (Rif. IOR)
is currently participating in the Research Group
Experimental Hematology
as Group Leader [Rif. 55110]